rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2021-201-207rsp-3023Research ArticleФОРУМ МОЛОДЫХ УЧЕНЫХYOUNG SCIENTISTS FORUMНовые лабораторные биомаркеры ревматоидного артритаNew laboratory biomarkers of rheumatoid arthritishttps://orcid.org/0000-0003-3183-0464ДибровД. А.DibrovD. A.

Дибров Данил Алексеевич, ординатор 2-го года

115522, Москва, Каширское шоссе, 34а

Danil A. Dibrov

115522, Moscow, Kashirskoye Highway, 34A

dibrovd995@gmail.comФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202112052021592201207Copyright © Дибров Д.А., 20212021Дибров Д.А.Dibrov D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3023

В обзоре представлены данные о новых биомаркерах ревматоидного артрита (РА), включая антитела к карбамилированным белкам (анти-Карб), пептидил-аргининдезаминазе (анти-ПАД), гомоцистеинилированному α1-антитрипсину (гц-α1АТ), макрофагальный растворимый скавенджер-рецептор А (sSR-A), 14-3-3η. Исследование новых биомаркеров может позволить улучшить диагностику РА на ранних стадиях и стратифицировать пациентов в отношении прогноза и выбора терапии.

The review presents data on new biomarkers for the diagnosis of rheumatoid arthritis, considers the diagnostic parameters of antibodies to carbamylated proteins, antibodies to peptidyl arginine deaminase, antibodies to homocysteinylated α1-antitrypsin, 14-3-3η, macrophage soluble scavenger receptor A. The use of new biomarkers can improve the diagnosis of RA in the early stages, as well as stratify patients based on the prognosis of the disease and provide a rational selection of therapy.

ревматоидный артритбиомаркерыанти-Карбанти-ПАДанти-гцА1АТ14-3-3ηмакрофагальный sSR-Arheumatoid arthritisbiomarkersanti-CarPanti-homocysteinylated alpha-1-antitrypsinanti-peptidyl-arginine deiminaseanti-homocysteinylated α1-antitrypsin14-3-3ηmacrophage soluble scavenger receptor AReferencesНасонов ЕЛ (ред.). Российские клинические рекомендации. Ревматология. М.;ГЭОТАР-Медиа;2019:17-57.Nasonov EL (ed.). Rheumatology: Russian clinical guidelines. Moscow;GEOTAR-Media;2019:17-57 (In Russ.).Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-3390. doi: 10.1002/art.21405Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-3390. doi: 10.1002/art.21405Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-2581. doi: 10.1002/art.27584Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-2581. doi: 10.1002/art.27584Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808. doi: 10.7326/0003-4819-146-11-200706050-00008Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808. doi: 10.7326/0003-4819-146-11-200706050-00008Sun J, Zhang Y, Liu L, Liu G. Diagnostic accuracy of combined tests of anti cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis: A meta-analysis. Clin Exp Rheumatol. 2014;32(1):11-21.Sun J, Zhang Y, Liu L, Liu G. Diagnostic accuracy of combined tests of anti cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis: A meta-analysis. Clin Exp Rheumatol. 2014;32(1):11-21.Coffey CM, Crowson CS, Myasoedova E. Evidence of diagnostic and treatment delay in seronegative rheumatoid arthritis: Missing the window of opportunity. Mayo Clin Proc. 2019;94(11):2241-2248. doi: 10.1016/j.mayocp.2019.05.023Coffey CM, Crowson CS, Myasoedova E. Evidence of diagnostic and treatment delay in seronegative rheumatoid arthritis: Missing the window of opportunity. Mayo Clin Proc. 2019;94(11):22412248. doi: 10.1016/j.mayocp.2019.05.023Nordberg LB, Lillegraven S, Aga AB, Sexton J, Olsen IC, Lie E, et al. Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/ EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open. 2018;4(2):e000752. doi: 10.1136/rmdopen-2018-000752Nordberg LB, Lillegraven S, Aga AB, Sexton J, Olsen IC, Lie E, et al. Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/ EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open. 2018;4(2):e000752. doi: 10.1136/rmdopen-2018-000752Насонов ЕЛ. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017;55(3):277-294. doi: 10.14412/1995-4484-2017-277-294Nasonov EL. Problems of rheumatoid arthritis immunopathology: Evolution of the disease. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):277-294 (In Russ.). doi: 10.14412/1995-4484-2017277-294Cantagrel A, Degboe Y. New autoantibodies associated with rheumatoid arthritis recognize posttranslationally modified selfprotein. Joint Bone Spain. 2016;83:11-17. doi: 10.1016/j.jbspin.2015.10.003Cantagrel A, Degboe Y. New autoantibodies associated with rheumatoid arthritis recognize posttranslationally modified selfprotein. Joint Bone Spain. 2016;83:11-17. doi: 10.1016/j.jbspin.2015.10.003Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW, Huizinga TW, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev. 2014;13(3):225-230. doi: 10.1016/j.autrev.2013.10.008Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW, Huizinga TW, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev. 2014;13(3):225-230. doi: 10.1016/j.autrev.2013.10.008Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13(10):1176-1184. doi: 10.1038/nm1637Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13(10):1176-1184. doi: 10.1038/nm1637Mydel P, Wang Z, Brisslert M, Hellvard A, Dahlberg LE, Hazen SL, et al. Carbamylation-dependent activation of T cells: A novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol. 2010;184(12):6882-6890. doi: 10.4049/jimmunol.1000075Mydel P, Wang Z, Brisslert M, Hellvard A, Dahlberg LE, Hazen SL, et al. Carbamylation-dependent activation of T cells: A novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol. 2010;184(12):6882-6890. doi: 10.4049/jimmunol.1000075Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA. 2011;108(42):17372-17377. doi: 10.1073/pnas.1114465108Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA. 2011;108(42):17372-17377. doi: 10.1073/pnas.1114465108Li X, Wang Z, Yi H. Diagnostic accuracy of anti-carbamylated protein antibodies in rheumatoid arthritis: A systematic review and meta-analysis. Clin Lab. 2019;65(12). doi: 10.7754/Clin.Lab.2019.190419Li X, Wang Z, Yi H. Diagnostic accuracy of anti-carbamylated protein antibodies in rheumatoid arthritis: A systematic review and meta-analysis. Clin Lab. 2019;65(12). doi: 10.7754/Clin.Lab.2019.190419Bergum B, Koro C, Delaleu N, Solheim M, Hellvard A, Binder V, et al. Antibodies against carbamylated proteins are present in primary Sjogren’s syndrome and are associated with disease severity. Ann Rheum Dis. 2016;75(8):1494-1500. doi: 10.1136/annrheumdis-2015-207751Bergum B, Koro C, Delaleu N, Solheim M, Hellvard A, Binder V, et al. Antibodies against carbamylated proteins are present in primary Sjogren’s syndrome and are associated with disease severity. Ann Rheum Dis. 2016;75(8):1494-1500. doi: 10.1136/annrheumdis-2015-207751Ziegelasch M, van Delft MA, Wallin P, Skogh T, Magro-Checa C, Steup-Beekman GM, et al. Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. Arthritis Res Ther. 2016;18(1):289. doi: 10.1186/s13075-016-1192-xZiegelasch M, van Delft MA, Wallin P, Skogh T, Magro-Checa C, Steup-Beekman GM, et al. Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. Arthritis Res Ther. 2016;18(1):289. doi: 10.1186/s13075-016-1192-xPecani A, Alessandri C, Spinelli FR, Priori R, Riccieri V, Di Franco M, et al. Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases. Arthritis Res Ther. 2016;18(1):276. doi: 10.1186/s13075-016-1173-0Pecani A, Alessandri C, Spinelli FR, Priori R, Riccieri V, Di Franco M, et al. Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases. Arthritis Res Ther. 2016;18(1):276. doi: 10.1186/s13075-016-1173-0Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014;73(4):780-783. doi: 10.1136/annrheumdis-2013-204154Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014;73(4):780-783. doi: 10.1136/annrheumdis-2013-204154Brink M, Verheul MK, Rönnelid J, Berglin E, Holmdahl R, Toes RE, et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther. 2015;17(1):25. doi: 10.1186/s13075-015-0536-2Brink M, Verheul MK, Rönnelid J, Berglin E, Holmdahl R, Toes RE, et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther. 2015;17(1):25. doi: 10.1186/s13075-015-0536-2Verheul MK, Böhringer S, van Delft MAM. Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: Implications for very early identification of at-risk individuals. Arthritis Rheumatol. 2018;70(11):1721-1731. doi: 10.1002/art.40562Verheul MK, Böhringer S, van Delft MAM. Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: Implications for very early identification of at-risk individuals. Arthritis Rheumatol. 2018;70(11):1721-1731. doi: 10.1002/art.40562Boeters DM, Trouw LA, van der Helm-van Mil AHM, van Steenbergen HW. Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: A study on anti-CarP antibodies as an example. Arthritis Res Ther. 2018;20(1):94. doi: 10.1186/s13075-018-1591-2Boeters DM, Trouw LA, van der Helm-van Mil AHM, van Steenbergen HW. Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: A study on anti-CarP antibodies as an example. Arthritis Res Ther. 2018;20(1):94. doi: 10.1186/s13075-018-1591-2Ponchel F, van Delft MAM, Xie X, Burska AN, Duquenne L, Trouw LA, et al. Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis? Clin Exp Rheumatol. 2021;39(1):146-150.Ponchel F, van Delft MAM, Xie X, Burska AN, Duquenne L, Trouw LA, et al. Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis? Clin Exp Rheumatol. 2021;39(1):146-150.Regueiro C, Rodríguez-Martínez L, Nuño L, Ortiz AM, Villalba A, Pascual-Salcedo D, et al. Improved RA classification among early arthritis patients with the concordant presence of three RA autoantibodies: Analysis in two early arthritis clinics. Arthritis Res Ther. 2019;21(1):280. doi: 10.1186/s13075-019-2079-4Regueiro C, Rodríguez-Martínez L, Nuño L, Ortiz AM, Villalba A, Pascual-Salcedo D, et al. Improved RA classification among early arthritis patients with the concordant presence of three RA autoantibodies: Analysis in two early arthritis clinics. Arthritis Res Ther. 2019;21(1):280. doi: 10.1186/s13075-019-2079-4van Dijk BT, Trouw LA, van der Helm-van Mil AHM, Huizinga TWJ. Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: Response to the article by Regueiro et al. Arthritis Res Ther. 2020;22(1):85. doi: 10.1186/s13075-020-02182-3van Dijk BT, Trouw LA, van der Helm-van Mil AHM, Huizinga TWJ. Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: Response to the article by Regueiro et al. Arthritis Res Ther. 2020;22(1):85. doi: 10.1186/s13075-020-02182-3Jiang X, Trouw LA, van Wesemael TJ, Shi J, Bengtsson C, Källberg H, et al. AntiCarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis. 2014;73(10):1761-1768. doi: 10.1136/annrheumdis-2013-205109Jiang X, Trouw LA, van Wesemael TJ, Shi J, Bengtsson C, Källberg H, et al. AntiCarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis. 2014;73(10):1761-1768. doi: 10.1136/annrheumdis-2013-205109Ajeganova S, van Steenbergen HW, Verheul MK, Forslind K, Hafström I, Toes RE, et al. The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: A study exploring replication and the added value to ACPA and rheumatoid factor. Ann Rheum Dis. 2017;76(1):112-118. doi: 10.1136/annrheumdis-2015-208870Ajeganova S, van Steenbergen HW, Verheul MK, Forslind K, Hafström I, Toes RE, et al. The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: A study exploring replication and the added value to ACPA and rheumatoid factor. Ann Rheum Dis. 2017;76(1):112-118. doi: 10.1136/annrheumdis-2015-208870Truchetet ME, Dublanc S, Barnetche T, Vittecoq O, Mariette X, Richez C, et al. Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: Data from the French ESPOIR cohort. Arthritis Rheumatol. 2017;69(12):2292-2302. doi: 10.1002/art.40237Truchetet ME, Dublanc S, Barnetche T, Vittecoq O, Mariette X, Richez C, et al. Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: Data from the French ESPOIR cohort. Arthritis Rheumatol. 2017;69(12):2292-2302. doi: 10.1002/art.40237Sidiras P, Spruyt D, Gangji V, Imbault V, Sokolova T, Durez P, et al. Antibodies against carbamylated proteins: Prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases. Scand J Rheumatol. 2020;7:1-6. doi: 10.1080/03009742.2020.1798500Sidiras P, Spruyt D, Gangji V, Imbault V, Sokolova T, Durez P, et al. Antibodies against carbamylated proteins: Prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases. Scand J Rheumatol. 2020;7:1-6. doi: 10.1080/03009742.2020.1798500Zhang B, Lei Y, Li X, Gao Z, Xia L, Lu J, et al. Elevated levels of anti-carbamylated protein antibody in patients with rheumatoid arthritis: association with disease activity and bone destruction. J Investig Med. 2020;68(6):1186-1192. doi: 10.1136/jim-2019-001249Zhang B, Lei Y, Li X, Gao Z, Xia L, Lu J, et al. Elevated levels of anti-carbamylated protein antibody in patients with rheumatoid arthritis: association with disease activity and bone destruction. J Investig Med. 2020;68(6):1186-1192. doi: 10.1136/jim-2019-001249Elsayed SA, Esmail MA, Ali RM, Mohafez OM. Diagnostic and prognostic value of anti-CarP antibodies in a sample of Egyptian rheumatoid arthritis patients. Clin Rheumatol. 2019;38(10):2683-2689. doi: 10.1007/s10067-019-04616-zElsayed SA, Esmail MA, Ali RM, Mohafez OM. Diagnostic and prognostic value of anti-CarP antibodies in a sample of Egyptian rheumatoid arthritis patients. Clin Rheumatol. 2019;38(10):26832689. doi: 10.1007/s10067-019-04616-zHumphreys J, Verheul M, Barton A, Fu B, Toes R, Symmons D, Trouw L, et al. Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Lancet. 2015;385(Suppl 1):S44. doi: 10.1016/S0140-6736(15)60359-2Humphreys J, Verheul M, Barton A, Fu B, Toes R, Symmons D, Trouw L, et al. Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Lancet. 2015;385(Suppl 1):S44. doi: 10.1016/S01406736(15)60359-2Derksen VFAM, Trouw LA, Huizinga TWJ, van der Helmvan Mil AHM, Knevel R, Westerlind H, et al. Anti-carbamylated protein antibodies and higher baseline disease activity in rheumatoid arthritis – A replication study in three cohorts: Comment on the Article by Truchetet et al. Arthritis Rheumatol. 2018;70(12):2096-2097. doi: 10.1002/art.40678Derksen VFAM, Trouw LA, Huizinga TWJ, van der Helmvan Mil AHM, Knevel R, Westerlind H, et al. Anti-carbamylated protein antibodies and higher baseline disease activity in rheumatoid arthritis – A replication study in three cohorts: Comment on the Article by Truchetet et al. Arthritis Rheumatol. 2018;70(12):2096-2097. doi: 10.1002/art.40678Zhu H, Zhao LJ, Zhou Y, Chen Y. Significance of anti-carbamylated protein antibodies in patients with rheumatoid arthritis-associated intersitial lung disease. Beijing Da Xue Xue Bao Yi Xue Ban. 2019;51(6):1003-1007. doi: 10.19723/j.issn.1671-167X.2019.06.004Zhu H, Zhao LJ, Zhou Y, Chen Y. Significance of anti-carbamylated protein antibodies in patients with rheumatoid arthritis-associated intersitial lung disease. Beijing Da Xue Xue Bao Yi Xue Ban. 2019;51(6):1003-1007. doi: 10.19723/j.issn.1671-167X.2019.06.004Castellanos-Moreira R, Rodríguez-García SC, Gomara MJ, RuizEsquide V, Cuervo A, Casafont-Solé I, et al. Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. Ann Rheum Dis. 2020;79(5):587-594. doi: 10.1136/annrheumdis-2019-216709Castellanos-Moreira R, Rodríguez-García SC, Gomara MJ, RuizEsquide V, Cuervo A, Casafont-Solé I, et al. Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. Ann Rheum Dis. 2020;79(5):587-594. doi: 10.1136/annrheumdis-2019-216709Vidal-Bralo L, Perez-Pampin E, Regueiro C, Montes A, Varela R, Boveda MD, et al. Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients. PLoS One. 2017;12(7):e0180144. doi: 10.1371/journal.pone.0180144Vidal-Bralo L, Perez-Pampin E, Regueiro C, Montes A, Varela R, Boveda MD, et al. Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients. PLoS One. 2017;12(7):e0180144. doi: 10.1371/journal.pone.0180144Spinelli FR, Pecani A, Ciciarello F, Colasanti T, Di Franco M, Miranda F, et al. Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients. BMC Musculoskelet Disord. 2017;18(1):214. doi: 10.1186/s12891-017-1563-8Spinelli FR, Pecani A, Ciciarello F, Colasanti T, Di Franco M, Miranda F, et al. Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients. BMC Musculoskelet Disord. 2017;18(1):214. doi: 10.1186/s12891-017-1563-8Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, et al. Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-α therapy in patients with rheumatoid arthritis: A US national observational study. J Rheumatol. 2018;45(1):32-39. doi: 10.3899/jrheum.170007Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, et al. Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-α therapy in patients with rheumatoid arthritis: A US national observational study. J Rheumatol. 2018;45(1):32-39. doi: 10.3899/jrheum.170007Kumar R, Piantoni S, Boldini M, Garrafa E, Bazzani C, Fredi M, et al. Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. Clin Exp Rheumatol. 2021;39(1):91-97.Kumar R, Piantoni S, Boldini M, Garrafa E, Bazzani C, Fredi M, et al. Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. Clin Exp Rheumatol. 2021;39(1):91-97.Verheul MK, Yee A, Seaman A, Janssen GM, van Veelen PA, Drijfhout JW, et al. Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis. J Autoimmun. 2017;80:77-84. doi: 10.1016/j.jaut.2017.02.008Verheul MK, Yee A, Seaman A, Janssen GM, van Veelen PA, Drijfhout JW, et al. Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis. J Autoimmun. 2017;80:77-84. doi: 10.1016/j.jaut.2017.02.008Ehlers MR. Immune-modulating effects of alpha-1 antitrypsin. Biol Chem. 2014;395(10):1187-1193. doi: 10.1515/hsz-2014-0161Ehlers MR. Immune-modulating effects of alpha-1 antitrypsin. Biol Chem. 2014;395(10):1187-1193. doi: 10.1515/hsz-2014-0161McCarthy C, Orr C, Fee LT, Carroll TP, Dunlea DM, Hunt DJL, et al. Brief report: Genetic variation of the α1 -antitrypsin gene is associated with increased autoantibody production in rheumatoid arthritis. Arthritis Rheumatol. 2017;69(8):1576-1579. doi: 10.1002/art.40127McCarthy C, Orr C, Fee LT, Carroll TP, Dunlea DM, Hunt DJL, et al. Brief report: Genetic variation of the α1 -antitrypsin gene is associated with increased autoantibody production in rheumatoid arthritis. Arthritis Rheumatol. 2017;69(8):1576-1579. doi: 10.1002/art.40127Colasanti T, Sabatinelli D, Mancone C, Giorgi A, Pecani A, Spinelli FR, et al. Homocysteinylated alpha 1 antitrypsin as an antigenic target of autoantibodies in seronegative rheumatoid arthritis patients. J Autoimmun. 2020;113:102470. doi: 10.1016/j.jaut.2020.102470Colasanti T, Sabatinelli D, Mancone C, Giorgi A, Pecani A, Spinelli FR, et al. Homocysteinylated alpha 1 antitrypsin as an antigenic target of autoantibodies in seronegative rheumatoid arthritis patients. J Autoimmun. 2020;113:102470. doi: 10.1016/j.jaut.2020.102470Suzuki A, Yamada R, Yamamoto K. Citrullination by peptidylarginine deiminase in rheumatoid arthritis. Ann N Y Acad Sci. 2007;1108:323-39. doi: 10.1196/annalsSuzuki A, Yamada R, Yamamoto K. Citrullination by peptidylarginine deiminase in rheumatoid arthritis. Ann N Y Acad Sci. 2007;1108:323-39. doi: 10.1196/annalsFoulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Méchin MC, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum. 2007;56(11):3541-3553. doi: 10.1002/art.22983Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Méchin MC, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum. 2007;56(11):3541-3553. doi: 10.1002/art.22983Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013;5(178):178ra40. doi: 10.1126/scitranslmed.3005580Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013;5(178):178ra40. doi: 10.1126/scitranslmed.3005580Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122(5):1791-1802. doi: 10.1172/JCI609Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122(5):1791-1802. doi: 10.1172/JCI609Laurent L, Anquetil F, Clavel C, Ndongo-Thiam N, Offer G, Miossec P, et al. IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies. Ann Rheum Dis. 2015;74(7):1425-1431. doi: 10.1136/annrheumdis-2013-204543Laurent L, Anquetil F, Clavel C, Ndongo-Thiam N, Offer G, Miossec P, et al. IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies. Ann Rheum Dis. 2015;74(7):1425-1431. doi: 10.1136/annrheumdis-2013-204543Nissinen R, Paimela L, Julkunen H, Tienari PJ, LeirisaloRepo M, Palosuo T, et al. Peptidylarginine deiminase, the arginine to citrulline converting enzyme, is frequently recognized by sera of patients with rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren syndrome. Scand J Rheumatol. 2003;32(6):337-342. doi: 10.1080/03009740410004990Nissinen R, Paimela L, Julkunen H, Tienari PJ, LeirisaloRepo M, Palosuo T, et al. Peptidylarginine deiminase, the arginine to citrulline converting enzyme, is frequently recognized by sera of patients with rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren syndrome. Scand J Rheumatol. 2003;32(6):337-342. doi: 10.1080/03009740410004990Ren J, Sun L, Zhao J. Meta-analysis: diagnostic accuracy of antibody against peptidylarginine deiminase 4 by ELISA for rheumatoid arthritis. Clinical Rheum. 2017;36(11):2431-2438. doi: 10.1007/s10067-017-3809-0Ren J, Sun L, Zhao J. Meta-analysis: diagnostic accuracy of antibody against peptidylarginine deiminase 4 by ELISA for rheumatoid arthritis. Clinical Rheum. 2017;36(11):2431-2438. doi: 10.1007/s10067-017-3809-0Kolfenbach JR, Deane KD, Derber LA, O’Donnell CI, Gilliland WR, Edison JD, et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2633-2639. doi: 10.1002/art.27570Kolfenbach JR, Deane KD, Derber LA, O’Donnell CI, Gilliland WR, Edison JD, et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2633-2639. doi: 10.1002/art.27570Martinez-Prat L, Lucia D, Ibarra C, Mahler M, Dervieux T. Antibodies targeting protein-arginine deiminase 4 (PAD4) demonstrate diagnostic value in rheumatoid arthritis. Ann Rheum Dis. 2019;78(3):434-436. doi: 10.1136/annrheumdis-2018-213818Martinez-Prat L, Lucia D, Ibarra C, Mahler M, Dervieux T. Antibodies targeting protein-arginine deiminase 4 (PAD4) demonstrate diagnostic value in rheumatoid arthritis. Ann Rheum Dis. 2019;78(3):434-436. doi: 10.1136/annrheumdis-2018-213818Reyes-Castillo Z, Palafox-Sánchez CA, Parra-Rojas I, MartínezBonilla GE, del Toro-Arreola S, Ramírez-Dueñas MG, et al. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: Associations with cytokine profiles, clinical and genetic features. Clin Exp Immunol. 2015;182(2):119-131. doi: 10.1111/cei.12677Reyes-Castillo Z, Palafox-Sánchez CA, Parra-Rojas I, MartínezBonilla GE, del Toro-Arreola S, Ramírez-Dueñas MG, et al. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: Associations with cytokine profiles, clinical and genetic features. Clin Exp Immunol. 2015;182(2):119-131. doi: 10.1111/cei.12677Guderud K, Mæhlen MT, Nordang GBN, Viken MK, Andreassen BK, Molberg Ø, et al. Lack of association among peptidyl arginine deiminase type 4 autoantibodies, PADI4 polymorphisms, and clinical characteristics in rheumatoid arthritis. J Rheumatol. 2018;45(9):1211-1219. doi: 10.3899/jrheum.170769Guderud K, Mæhlen MT, Nordang GBN, Viken MK, Andreassen BK, Molberg Ø, et al. Lack of association among peptidyl arginine deiminase type 4 autoantibodies, PADI4 polymorphisms, and clinical characteristics in rheumatoid arthritis. J Rheumatol. 2018;45(9):1211-1219. doi: 10.3899/jrheum.170769Darrah E, Martinez-Prat L, Mahler M. Clinical utility of antipeptidyl arginine deiminase type 4 antibodies. J Rheumatol. 2019;46(3):329-330. doi: 10.3899/jrheum.180905Darrah E, Martinez-Prat L, Mahler M. Clinical utility of antipeptidyl arginine deiminase type 4 antibodies. J Rheumatol. 2019;46(3):329-330. doi: 10.3899/jrheum.180905Martinez-Prat L, Palterer B, Vitiello G, Parronchi P, Robinson WH, Mahler M., et al. Autoantibodies to protein-arginine deiminase (PAD) 4 in rheumatoid arthritis: immunological and clinical significance, and potential for precision medicine. Expert Rev Clin Immunol. 2019;15(10):1073-1087. doi: 10.1080/1744666X.2020.1668778Martinez-Prat L, Palterer B, Vitiello G, Parronchi P, Robinson WH, Mahler M., et al. Autoantibodies to protein-arginine deiminase (PAD) 4 in rheumatoid arthritis: immunological and clinical significance, and potential for precision medicine. Expert Rev Clin Immunol. 2019;15(10):1073-1087. doi: 10.1080/1744666X.2020.1668778Giles JT, Darrah E, Danoff S, Johnson C, Andrade F, Rosen A, et al. Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease. PLoS One. 2014;9(6):e98794. doi: 10.1371/journal.pone.0098794Giles JT, Darrah E, Danoff S, Johnson C, Andrade F, Rosen A, et al. Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease. PLoS One. 2014;9(6):e98794. doi: 10.1371/journal.pone.0098794Darrah E, Yu F, Cappelli LC, Rosen A, Rosen A, O’Dell JR, Mikuls TR. Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis. Arthritis Rheumatol. 2019;71(5):696-702. doi: 10.1002/art.40791Darrah E, Yu F, Cappelli LC, Rosen A, Rosen A, O’Dell JR, Mikuls TR. Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis. Arthritis Rheumatol. 2019;71(5):696-702. doi: 10.1002/art.40791Moore BW, Perez VJ, Gehring M. Assay and regional distribution of a soluble protein characteristic of the nervous system. J Neurochem. 1968;15(4):265-272. doi: 10.1111/j.1471-4159.1968.tb11610.xMoore BW, Perez VJ, Gehring M. Assay and regional distribution of a soluble protein characteristic of the nervous system. J Neurochem. 1968;15(4):265-272. doi: 10.1111/j.1471-4159.1968.tb11610.xMuslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996;84(6):889-897. doi: 10.1016/s00928674(00)81067Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996;84(6):889-897. doi: 10.1016/s00928674(00)81067Kilani RT, Maksymowych WP, Aitken A, Boire G, St-Pierre Y, Li Y, et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol. 2007;34(8):1650-1657.Kilani RT, Maksymowych WP, Aitken A, Boire G, St-Pierre Y, Li Y, et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol. 2007;34(8):1650-1657.Trimova G, Yamagata K, Iwata S, Hirata S, Zhang T, Uemura F, et al. Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages. Arthritis Res Ther. 2020;22(1):24. doi: 10.1186/s13075-020-2110-9Trimova G, Yamagata K, Iwata S, Hirata S, Zhang T, Uemura F, et al. Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages. Arthritis Res Ther. 2020;22(1):24. doi: 10.1186/s13075-020-2110-9Maksymowych WP, van der Heijde D, Allaart CF, Landewé R, Boire G, Tak PP, et al. 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther. 2014;16(2):R99. doi: 10.1186/ar4547Maksymowych WP, van der Heijde D, Allaart CF, Landewé R, Boire G, Tak PP, et al. 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther. 2014;16(2):R99. doi: 10.1186/ar4547de Launay D, van de Sande MG, de Hair MJ, Grabiec AM, van de Sande GP, Lehmann KA, et al. Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): A prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. Ann Rheum Dis. 2012;71(3):415-423. doi: 10.1136/ard.2010.143529de Launay D, van de Sande MG, de Hair MJ, Grabiec AM, van de Sande GP, Lehmann KA, et al. Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): A prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. Ann Rheum Dis. 2012;71(3):415-423. doi: 10.1136/ard.2010.143529Carrier N, de Brum-Fernandes AJ, Liang P, Masetto A, Roux S, Biln NK, et al. Impending radiographic erosive progression over the following year in a cohort of consecutive patients with inflammatory polyarthritis: Prediction by serum biomarkers. RMD Open. 2020;6(1):e001191. doi: 10.1136/rmdopen-2020-001191Carrier N, de Brum-Fernandes AJ, Liang P, Masetto A, Roux S, Biln NK, et al. Impending radiographic erosive progression over the following year in a cohort of consecutive patients with inflammatory polyarthritis: Prediction by serum biomarkers. RMD Open. 2020;6(1):e001191. doi: 10.1136/rmdopen-2020-001191Carrier N, Marotta A, de Brum-Fernandes AJ, Liang P, Masetto A, Ménard HA, et al. Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis. Arthritis Res Ther. 2016;18:37. doi: 10.1186/s13075-0160935-zCarrier N, Marotta A, de Brum-Fernandes AJ, Liang P, Masetto A, Ménard HA, et al. Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis. Arthritis Res Ther. 2016;18:37. doi: 10.1186/s13075-0160935-zHirata S, Marotta A, Gui Y, Hanami K, Tanaka Y. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res Ther. 2015;17:280. doi: 10.1186/s13075-015-0799-7Hirata S, Marotta A, Gui Y, Hanami K, Tanaka Y. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res Ther. 2015;17:280. doi: 10.1186/s13075-015-0799-7Maksymowych WP, van der Heijde D, Landewe R, Bathon JM, Bingham CO, Bykerk VP, et al. Validation of prognostic biomarkers for RA: testing of 14-3-3 eta according to the omeract soluble biomarker criteria, Arthritis Rheum. 2012;64(Suppl 10):896.Maksymowych WP, van der Heijde D, Landewe R, Bathon JM, Bingham CO, Bykerk VP, et al. Validation of prognostic biomarkers for RA: testing of 14-3-3 eta according to the omeract soluble biomarker criteria, Arthritis Rheum. 2012;64(Suppl 10):896.Gong X, Xu SQ, Wu Y, Ma CC, Qi S, Liu W, et al. Elevated serum 14-3-3η protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population. Clin Rheumatol. 2017;36(11):2581-2587. doi: 10.1007/s10067-017-3807-2Gong X, Xu SQ, Wu Y, Ma CC, Qi S, Liu W, et al. Elevated serum 14-3-3η protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population. Clin Rheumatol. 2017;36(11):2581-2587. doi: 10.1007/s10067-017-3807-2Sun Y, Hong L, Gao C. The association among 14-3-3η protein, inflammation, bone remodeling and osteoporosis in patients with rheumatoid arthritis. Pak J Med Sci. 2020;36(5):872-876. doi: 10.12669/pjms.36.5.2403Sun Y, Hong L, Gao C. The association among 14-3-3η protein, inflammation, bone remodeling and osteoporosis in patients with rheumatoid arthritis. Pak J Med Sci. 2020;36(5):872-876. doi: 10.12669/pjms.36.5.2403Zeng T, Tan L, Wu Y, Yu J. 14-3-3η protein in rheumatoid arthritis: promising diagnostic marker and independent risk factor for osteoporosis. Lab Med. 2020;51(5):529-539. doi: 10.1093/labmed/lmaa001Zeng T, Tan L, Wu Y, Yu J. 14-3-3η protein in rheumatoid arthritis: promising diagnostic marker and independent risk factor for osteoporosis. Lab Med. 2020;51(5):529-539. doi: 10.1093/labmed/lmaa001Marotta A, Maksymowych W. SAT0070 levels of 14-3-3Eta predict good eular response to anti-TNF treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73:615-616. doi: 10.1136/annrheumdis-2014-eular.3426Marotta A, Maksymowych W. SAT0070 levels of 14-3-3Eta predict good eular response to anti-TNF treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73:615-616. doi: 10.1136/annrheumdis-2014-eular.3426Wang D, Cui Y, Lei H, Cao D, Tang G, Huang H, et al. Diagnostic accuracy of 14-3-3η protein in rheumatoid arthritis: A meta-analysis. Int J Rheum Dis. 2020;23(11):1443-1451. doi: 10.1111/1756-185X.13921Wang D, Cui Y, Lei H, Cao D, Tang G, Huang H, et al. Diagnostic accuracy of 14-3-3η protein in rheumatoid arthritis: A meta-analysis. Int J Rheum Dis. 2020;23(11):1443-1451. doi: 10.1111/1756-185X.13921Wu Y, Dai Z, Wang H, Wang H, Wu L, Ling H, et al. Serum 14-3-3η is a marker that complements current biomarkers for the diagnosis of RA: Evidence from a meta-analysis. Immunol Invest. 2020:1-17. doi: 10.1080/08820139.2020.1817069Wu Y, Dai Z, Wang H, Wang H, Wu L, Ling H, et al. Serum 14-33η is a marker that complements current biomarkers for the diagnosis of RA: Evidence from a meta-analysis. Immunol Invest. 2020:1-17. doi: 10.1080/08820139.2020.1817069Marotta A, van Kuijk AW, Maksymowych WP, Tak PP. Serum 14-3-3η: An independent biomarker associated with joint damage in psoriatic arthritis. Ann Rheum Dis. 2012;71(Suppl 3):576. doi: 10.1136/annrheumdis-2012-eular.3256Marotta A, van Kuijk AW, Maksymowych WP, Tak PP. Serum 14-3-3η: An independent biomarker associated with joint damage in psoriatic arthritis. Ann Rheum Dis. 2012;71(Suppl 3):576. doi: 10.1136/annrheumdis-2012-eular.3256Salman E, Çetiner S, Boral B, Kibar F, Erken E, Ersözlü ED, et al. Importance of 14-3-3eta, anti-CarP, and anti-Sa in the diagnosis of seronegative rheumatoid arthritis. Turk J Med Sci. 2019;49(5):1498-1502. doi: 10.3906/sag-1812-137.Salman E, Çetiner S, Boral B, Kibar F, Erken E, Ersözlü ED, et al. Importance of 14-3-3eta, anti-CarP, and anti-Sa in the diagnosis of seronegative rheumatoid arthritis. Turk J Med Sci. 2019;49(5):1498-1502. doi: 10.3906/sag-1812-137.Maksymowych WP, Boire G, van Schaardenburg D, Wichuk S, Turk S, Boers M, et al. 14-3-3η autoantibodies: Diagnostic use in early rheumatoid arthritis. J Rheumatol. 2015;42(9):1587-1594. doi: 10.3899/jrheum.141385Maksymowych WP, Boire G, van Schaardenburg D, Wichuk S, Turk S, Boers M, et al. 14-3-3η autoantibodies: Diagnostic use in early rheumatoid arthritis. J Rheumatol. 2015;42(9):1587-1594. doi: 10.3899/jrheum.141385van Beers-Tas MH, Marotta A, Boers M, Maksymowych WP, van Schaardenburg D. A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia. Arthritis Res Ther. 2016;18:76. doi: 10.1186/s13075-016-0975-4van Beers-Tas MH, Marotta A, Boers M, Maksymowych WP, van Schaardenburg D. A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia. Arthritis Res Ther. 2016;18:76. doi: 10.1186/s13075-016-0975-4Chakravarti R, Gupta K, Swain M, Willard B, Scholtz J, Svensson LG, et al. 14-3-3 in thoracic aortic aneurysms: Identification of a novel autoantigen in large vessel vasculitis. Arthritis Rheumatol. 2015;67(7):1913-1921. doi: 10.1002/art.39130Chakravarti R, Gupta K, Swain M, Willard B, Scholtz J, Svensson LG, et al. 14-3-3 in thoracic aortic aneurysms: Identification of a novel autoantigen in large vessel vasculitis. Arthritis Rheumatol. 2015;67(7):1913-1921. doi: 10.1002/art.39130McGowan J, Peter C, Chattopadhyay S, Chakravarti R. 14-3-3ζ-A novel immunogen promotes inflammatory cytokine production. Front Immunol. 2019;10:1553. doi: 10.3389/fimmu.2019.01553McGowan J, Peter C, Chattopadhyay S, Chakravarti R. 14-3-3ζ-A novel immunogen promotes inflammatory cytokine production. Front Immunol. 2019;10:1553. doi: 10.3389/fimmu.2019.01553Huizinga TWJ, Amos CI, van der Helm-van Mil AHM, Chen W, van Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005;52:3433-3438. doi: 10.1002/art.21385Huizinga TWJ, Amos CI, van der Helm-van Mil AHM, Chen W, van Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005;52:3433-3438. doi: 10.1002/art.21385Raychaudhuri S, Sandor C, Stahl EA, Chen W, van Gaalen FA, Jawaheer D, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012;44:291-296. doi: 10.1038/ng.1076Raychaudhuri S, Sandor C, Stahl EA, Chen W, van Gaalen FA, Jawaheer D, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012;44:291-296. doi: 10.1038/ng.1076Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 1979;76(1):333-337. doi: 10.1073/pnas.76.1.333Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 1979;76(1):333-337. doi: 10.1073/pnas.76.1.333Kelley JL, Ozment TR, Li C, Schweitzer JB, Williams DL. Scavenger receptor-A (CD204): a two-edged sword in health and disease. Crit Rev Immunol. 2014;34(3):241-261. doi: 10.1615/critrevimmunol.2014010267Kelley JL, Ozment TR, Li C, Schweitzer JB, Williams DL. Scavenger receptor-A (CD204): a two-edged sword in health and disease. Crit Rev Immunol. 2014;34(3):241-261. doi: 10.1615/critrevimmunol.2014010267Seimon TA, Obstfeld A, Moore KJ, Golenbock DT, Tabas I. Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages. Proc Natl Acad Sci USA. 2006;103(52):19794-19799. doi: 10.1073/pnas.0609671104Seimon TA, Obstfeld A, Moore KJ, Golenbock DT, Tabas I. Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages. Proc Natl Acad Sci USA. 2006;103(52):19794-19799. doi: 10.1073/pnas.0609671104Hsu HY, Hajjar DP, Khan KM, Falcone DJ. Ligand binding to macrophage scavenger receptor-A induces urokinase-type plasminogen activator expression by a protein kinase-dependent signaling pathway. J Biol Chem. 1998;273(2):1240-1246. doi: 10.1074/jbc.273.2.124Hsu HY, Hajjar DP, Khan KM, Falcone DJ. Ligand binding to macrophage scavenger receptor-A induces urokinase-type plasminogen activator expression by a protein kinase-dependent signaling pathway. J Biol Chem. 1998;273(2):1240-1246. doi: 10.1074/jbc.273.2.124Hsu HY, Chiu SL, Wen MH, Chen KY, Hua KF. Ligands of macrophage scavenger receptor induce cytokine expression via differential modulation of protein kinase signaling pathways. J Biol Chem. 2001;276(31):28719-28730. doi: 10.1074/jbc.M011117200Hsu HY, Chiu SL, Wen MH, Chen KY, Hua KF. Ligands of macrophage scavenger receptor induce cytokine expression via differential modulation of protein kinase signaling pathways. J Biol Chem. 2001;276(31):28719-28730. doi: 10.1074/jbc.M011117200Wang XY, Facciponte J, Chen X, Subjeck JR, Repasky EA. Scavenger receptor-A negatively regulates antitumor immunity. Cancer Res. 2007;67(10):4996-5002. doi: 10.1158/0008-5472.CAN-06-3138Wang XY, Facciponte J, Chen X, Subjeck JR, Repasky EA. Scavenger receptor-A negatively regulates antitumor immunity. Cancer Res. 2007;67(10):4996-5002. doi: 10.1158/0008-5472.CAN06-3138Lin YL, de Villiers WJ, Garvy B, Post SR, Nagy TR, Safadi FF, et al. The effect of class a scavenger receptor deficiency in bone. J Biol Chem. 2007;282(7):4653-4660. doi: 10.1074/jbc.M608552200Lin YL, de Villiers WJ, Garvy B, Post SR, Nagy TR, Safadi FF, et al. The effect of class a scavenger receptor deficiency in bone. J Biol Chem. 2007;282(7):4653-4660. doi: 10.1074/jbc.M608552200Takemura K, Sakashita N, Fujiwara Y, Komohara Y, Lei X, Ohnishi K, et al. Class A scavenger receptor promotes osteoclast differentiation via the enhanced expression of receptor activator of NF-kappaB (RANK). Biochem Biophys Res Commun. 2010;391(4):1675-1680. doi: 10.1016/j.bbrc.2009.12.126Takemura K, Sakashita N, Fujiwara Y, Komohara Y, Lei X, Ohnishi K, et al. Class A scavenger receptor promotes osteoclast differentiation via the enhanced expression of receptor activator of NF-kappaB (RANK). Biochem Biophys Res Commun. 2010;391(4):1675-1680. doi: 10.1016/j.bbrc.2009.12.126Hu F, Jiang X, Guo C, Li Y, Chen S, Zhang W, et al. Scavenger receptor-A is a biomarker and effector of rheumatoid arthritis: A large-scale multicenter study. Nat Commun. 2020;11(1):1911. doi: 10.1038/s41467-020-15700-3Hu F, Jiang X, Guo C, Li Y, Chen S, Zhang W, et al. Scavenger receptor-A is a biomarker and effector of rheumatoid arthritis: A large-scale multicenter study. Nat Commun. 2020;11(1):1911. doi: 10.1038/s41467-020-15700-3Zhu JN, Nie LY, Lu XY, Wu HX. Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria? Clin Chem Lab Med. 2019;57(11):1668-1679. doi: 10.1515/cclm-2019-0167Zhu JN, Nie LY, Lu XY, Wu HX. Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria? Clin Chem Lab Med. 2019;57(11):1668-1679. doi: 10.1515/cclm-20190167Nicaise Roland P, Grootenboer Mignot S, Bruns A, Hurtado M, Palazzo E, Hayem G, et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther. 2008;10(6):R142. doi: 10.1186/ar2570Nicaise Roland P, Grootenboer Mignot S, Bruns A, Hurtado M, Palazzo E, Hayem G, et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther. 2008;10(6):R142. doi: 10.1186/ar2570

The authors declare that there are no conflicts of interest present.